Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 5Active not recruiting 2Unknown 1Terminated 1Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 11Leukemia 7Hodgkin Disease 7Recurrence 6Leukemia, Lymphocytic, Chronic, B-Cell 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myelodysplastic Syndromes 5Lymphoma, Non-Hodgkin 5Lymphoma, Mantle-Cell 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Leukemia, Myeloid, Chronic-Phase 5Leukemia, Myeloid, Acute 5Multiple Myeloma 4Leukemia, Myeloid, Accelerated Phase 4Neoplasms, Plasma Cell 3Nasopharyngeal Carcinoma 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, B-Cell, Marginal Zone 3Immunoblastic Lymphadenopathy 3Graft vs Host Disease 3Dendritic Cell Sarcoma, Interdigitating 3Congenital Abnormalities 3Burkitt Lymphoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Melanoma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2

Interventions

Dexamethasone 3isatuximab 2Lenalidomide 2Cyclophosphamide 2pomalidomide 1fludarabine phosphate 1fludarabine 1daratumumab 1Watchful Waiting 1Vorinostat 1Vincristine 1Specimen Handling 1Rituximab 1Ranitidine 1R-CHOP protocol 1Prednisone 1Interviews as Topic 1Injections 1Histone Deacetylase Inhibitors 1Filgrastim 1Exercise 1Doxorubicin 1Diphenhydramine 1Data Collection 1Bortezomib 1Acetaminophen 1AC protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Hematologic Diseases × fludarabine phosphate × Clear all
NCT05755854 2023-09-22

Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors

Anhui Provincial Hospital

Phase 1 Unknown
10 enrolled

Hematologic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡